Dechert LLP advised private equity firms HeidelbergCapital and Creathor Venture, together with former and current management and employees, on the sale of their shares in Accovion GmbH to Clinipace Inc. USA, a global digital Contract Research Organization (CRO). Accovion is a leading European full-service CRO headquartered in Frankfurt, Germany.

HeidelbergCapital is an independent private equity firm specializing in Secondary Direct Transactions with a portfolio capital that ranges from late stage technology based companies to mature mid-size businesses. As an active partner, HeidelbergCapital supports its portfolio companies with strategic development and provides funding for further growth.

The German Dechert team included lead partners Dr. Katja Heuterkes (Corporate, Munich), Berthold Hummel (Corporate, Munich) and Dr. Martin Haisch (Tax, Frankfurt) in addition to associates Christian Böhme (Corporate, Munich) and Julia Braun (Corporate, Munich).

As a leading European Venture Capital firm, Creathor Venture manages funds of more than €180 million and invests in healthcare and technology companies.